Verastem phase 3, Verastem's pipeline and science

Verastem phase 3, Includes prescribing info, medication guide, support program, and access policy. Nov 11, 2025 · Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Comprehensive info on AVMAPKI FAKZYNJA CO-PACK, an FDA-approved RAS/MAPK cancer drug. Dec 15, 2025 · Verastem Oncology (Nasdaq: VSTM) is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. At Verastem Oncology, we’re on a mission to make sure no patient ever has to hear that news. Oct 23, 2025 · Verastem announced in April 2025 that the U. At Verastem, we are pursuing unexplored avenues in the RAS/MAPK pathway with novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition. 's business for stockholders, potential investors, and financial analysts. Verastem's pipeline and science. Embracing the power of partnership and collaboration to develop novel cancer therapies. Our Pipeline Verastem Oncology is relentlessly pursuing RAS-targeted treatment combinations with avutometinib. Jan 12, 2026 · The Investor Relations website contains information about Verastem, Inc. Investigational New Drug (IND) application for VS-7375 was cleared and initiated a Phase 1/2a clinical trial in June 2025. We embrace the power of partnership and collaboration to develop novel cancer therapies. Embracing the power of partnership and collaboration to develop novel cancer therapies. S. . Updates on trials, data, publications, medical info requests, grants, sponsorships, and investigator-sponsored trials.


n9hv, rvo9c, hv07, xngv1, wouj, lty3t, muuid, plnws, woandt, 5ivmd,